Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

Bellicum Pharmaceuticals (BLCM) PT Lowered to $25 at Citi Following Rimiducid Activation Switch

March 15, 2018 6:58 AM EDT

Citi lowered its price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) to $25.00 (from $27.00) while maintaining a Buy rating following the company's announced details of the first patient to receive the Rimiducid activation switch. The company is still investigating what happened to the cells, and noted... More

Bellicum Pharma (BLCM) Tops Q4 EPS by 8c

March 13, 2018 4:04 PM EDT

Bellicum Pharma (NASDAQ: BLCM) reported Q4 EPS of ($0.66), $0.08 better than the analyst estimate of ($0.74).

For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.

... More